Patents by Inventor Ruo Steensma
Ruo Steensma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8114879Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v.Type: GrantFiled: March 26, 2008Date of Patent: February 14, 2012Assignee: Schering CorporationInventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Publication number: 20110098280Abstract: Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.Type: ApplicationFiled: January 4, 2011Publication date: April 28, 2011Applicants: Novartis AG, IRM LLCInventors: Carlos Garcia-Echeverria, Takanori Kanazawa, Eiji Kawahara, Keiichi Masuya, Naoko Matsuura, Takahiro Miyake, Osamu Ohmori, Ichiro Umemura, Ruo Steensma, Greg Chopiuk, Jiqing Jiang, Yongqin Wan, Qiang Ding, Qiong Zhang, Nathanael Schiander Gray, Donald Karanewsky
-
Patent number: 7893074Abstract: Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.Type: GrantFiled: August 13, 2004Date of Patent: February 22, 2011Assignees: Novartis AG, IRM LLCInventors: Carlos Garcia-Echeverria, Takanori Kanazawa, Eiji Kawahara, Keiichi Masuya, Naoko Matsuura, Takahiro Miyake, Osamu Ohmori, Ichiro Umemura, Ruo Steensma, Greg Chopiuk, Jiqing Jiang, Yongqin Wan, Qiang Ding, Qiong Zhang, Nathanael Schiander Gray, Donald Karanewsky
-
Publication number: 20090258910Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2?, p38, TGF?, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.Type: ApplicationFiled: June 25, 2009Publication date: October 15, 2009Applicant: IRM LLCInventors: Nathanael S. Gray, Jiqing Jiang, Yi Liu, Ruo Steensma
-
Patent number: 7569593Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2?, p38, TGF?, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.Type: GrantFiled: October 1, 2004Date of Patent: August 4, 2009Assignee: IRM LLCInventors: Nathanael Schiander Gray, Jiqing Jiang, Yi Liu, Ruo Steensma
-
Patent number: 7449582Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF?, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2? kinases.Type: GrantFiled: October 8, 2004Date of Patent: November 11, 2008Assignee: IRM LLCInventors: Qiang Ding, Yongping Xie, Nathanael S. Gray, Shuli You, Greg Chopiuk, Jiqing Jiang, Yi Liu, Ruo Steensma, Xing Wang, Taebo Sim
-
Publication number: 20080188485Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v.Type: ApplicationFiled: March 26, 2008Publication date: August 7, 2008Inventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Patent number: 7384944Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v.Type: GrantFiled: September 23, 2003Date of Patent: June 10, 2008Assignee: Schering CorporationInventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Publication number: 20080132504Abstract: Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising themType: ApplicationFiled: August 13, 2004Publication date: June 5, 2008Inventors: Carlos Garcia-Echeverria, Takanori Kanazawa, Eiji Kawahara, Keiichi Masuya, Naoko Matsuura, Takahiro Miyake, Osamu Ohmori, Ichiro Umemura, Ruo Steensma, Greg Chopiuk, Jiqing Jiang, Yongqin Wan, Qiang Ding, Qiong Zhang, Nathanael Schiander Gray, Donald Karanewsky
-
Publication number: 20070287711Abstract: The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.Type: ApplicationFiled: April 10, 2007Publication date: December 13, 2007Applicant: SGX Pharmaceuticals, Inc.Inventors: William Arnold, Pierre Bounaud, Chixu Chen, Brian Eastman, Andreas Gosberg, Stefan Gradl, Stephanie Hopkins, Zhe Li, Ian McDonald, Paul Sprengeler, Ruo Steensma, Mark Wilson
-
Publication number: 20070117800Abstract: The present invention provides novel pyrimidinyl-thiophene kinase modulators and methods of using the novel pyrimidinyl-thiophene kinase modulators to treat diseases mediated by kinase activity.Type: ApplicationFiled: November 2, 2006Publication date: May 24, 2007Applicant: SGX Pharmaceuticals, Inc.Inventors: William Arnold, Chixu Chen, Stefan Gradl, Stephanie Hopkins, Ruo Steensma, Masaki Tomimoto, Mark Wilson
-
Patent number: 7189729Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, EGF-R, c-erbB2 kinase (HER-2), CHK2, FGFR3, p70S6K, PKC, PDGF-R, p38, TGF?, KDR, c-Kit, b-RAF, c-RAF, FLT1 and/or FLT4 kinases.Type: GrantFiled: September 30, 2004Date of Patent: March 13, 2007Assignee: IRM LLCInventors: Greg Chopiuk, Pascal Furet, Nathanael Schiander Gray, Patricia Imbach, Yi Liu, Joseph Schoepfer, Ruo Steensma
-
Publication number: 20070043068Abstract: The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.Type: ApplicationFiled: February 27, 2006Publication date: February 22, 2007Applicant: SGX Pharmaceuticals, Inc.Inventors: William Arnold, Pierre Bounaud, Andreas Gosberg, Zhe Li, Ian McDonald, Ruo Steensma, Mark Wilson
-
Publication number: 20060035898Abstract: The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.Type: ApplicationFiled: July 27, 2005Publication date: February 16, 2006Applicant: Structural GenomiX, Inc.Inventors: William Arnold, Andreas Gosberg, Zhe Li, Ruo Steensma, Mark Wilson
-
Publication number: 20060030583Abstract: The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.Type: ApplicationFiled: July 27, 2005Publication date: February 9, 2006Applicant: SGX Pharmaceuticals, Inc.Inventors: William Arnold, Pierre Bounaud, Andreas Gosberg, Zhe Li, Ian McDonald, Ruo Steensma, Mark Wilson
-
Publication number: 20050209285Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2?, p38, TGF?, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.Type: ApplicationFiled: October 1, 2004Publication date: September 22, 2005Applicant: IRM LLCInventors: Nathanael Gray, Jiqing Jiang, Yi Liu, Ruo Steensma
-
Publication number: 20050187230Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF?, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2? kinases.Type: ApplicationFiled: October 8, 2004Publication date: August 25, 2005Applicant: IRM LLCInventors: Qiang Ding, Yongping Xie, Nathanael Gray, Shuli You, Greg Chopiuk, Jiqing Jiang, Yi Liu, Ruo Steensma, Xing Wang, Taebo Sim
-
Publication number: 20050171105Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, EGF-R, c-erbB2 kinase (HER-2), CHK2, FGFR3, p70S6K, PKC, PDGF-R, p38, TGF?, KDR, c-Kit, b-RAF, c-RAF, FLT1 and/or FLT4 kinases.Type: ApplicationFiled: September 30, 2004Publication date: August 4, 2005Applicants: IRM LLC, Novartis AGInventors: Greg Chopiuk, Pascal Furet, Nathanael Gray, Patricia Imbach, Yi Liu, Joseph Schoepfer, Ruo Steensma
-
Publication number: 20040067961Abstract: The use of CCR5 antagonists of the formula 1Type: ApplicationFiled: September 23, 2003Publication date: April 8, 2004Inventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli
-
Patent number: 6689765Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v, host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV oType: GrantFiled: January 30, 2002Date of Patent: February 10, 2004Assignee: Schering CorporationInventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Elizabeth M. Smith, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin, Eric Gilbert, Marc A. Labroli